4//SEC Filing
Tarriff Scott 4
Accession 0001209191-23-030725
CIK 0000827871other
Filed
May 17, 8:00 PM ET
Accepted
May 18, 5:22 PM ET
Size
6.7 KB
Accession
0001209191-23-030725
Insider Transaction Report
Form 4
Tarriff Scott
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-05-16$19.98/sh−15,000$299,700→ 587,311 total
Holdings
- 992,623(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.7454 to $20.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]This report reflects an adjustment to the Reporting Person's direct holdings to exclude shares incorrectly included in prior reports as directly held and to reflect such shares as held indirectly through the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust").
- [F3]The shares are held by the Trust for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.
Documents
Issuer
EAGLE PHARMACEUTICALS, INC.
CIK 0000827871
Entity typeother
Related Parties
1- filerCIK 0001469124
Filing Metadata
- Form type
- 4
- Filed
- May 17, 8:00 PM ET
- Accepted
- May 18, 5:22 PM ET
- Size
- 6.7 KB